OCTN2与前列腺癌细胞对奥沙利铂化疗敏感性的相关性

褚雷; 徐斌; 沙德厚; 王磊; 程广舟; 张继东

doi:10.6039/j.issn.1001-0408.2023.12.11

您当前的位置：

首页 >

文章列表页 >

OCTN2与前列腺癌细胞对奥沙利铂化疗敏感性的相关性

药学研究 | 更新时间：2023-06-26

- OCTN2与前列腺癌细胞对奥沙利铂化疗敏感性的相关性
- Correlation of OCTN2 with the chemosensitivity of prostate cancer cells to oxaliplatin
- 中国药房 2023年34卷第12期页码：1468-1472
- 作者机构：
  
  1.徐州医科大学附属滕州医院泌尿外科，山东枣庄　277500
  2.济宁医学院附属滕州中心人民医院泌尿外科，山东枣庄　277500
  3.山东中医药大学中医药创新研究院，济南　250355
  4.枣庄市妇幼保健院检验科，山东枣庄　277100
  5.济宁医学院附属滕州中心人民医院检验科，山东枣庄　277500
- 作者简介：
  
  主治医师，博士。研究方向：泌尿系肿瘤。E-mail：505916443@qq.com
  主管技师。研究方向：临床检验。E-mail：zjdtztougao@163.com
- 基金信息：
  
  徐州医科大学附属医院发展基金资助项目(XYFY2021038);济宁医学院青年教师科研扶持基金资助项目(JY2017FS034)
- DOI：10.6039/j.issn.1001-0408.2023.12.11
  中图分类号： R965
- 纸质出版日期：2023-06-30，
  
  收稿日期：2023-01-30，
  
  修回日期：2023-06-01，
扫描看全文
褚雷,徐斌,沙德厚等.OCTN2与前列腺癌细胞对奥沙利铂化疗敏感性的相关性 ^Δ[J].中国药房,2023,34(12):1468-1472.

CHU Lei,XU Bin,SHA Dehou,et al.Correlation of OCTN2 with the chemosensitivity of prostate cancer cells to oxaliplatin[J].ZHONGGUO YAOFANG,2023,34(12):1468-1472.
褚雷,徐斌,沙德厚等.OCTN2与前列腺癌细胞对奥沙利铂化疗敏感性的相关性 ^Δ[J].中国药房,2023,34(12):1468-1472. DOI： 10.6039/j.issn.1001-0408.2023.12.11.

CHU Lei,XU Bin,SHA Dehou,et al.Correlation of OCTN2 with the chemosensitivity of prostate cancer cells to oxaliplatin[J].ZHONGGUO YAOFANG,2023,34(12):1468-1472. DOI： 10.6039/j.issn.1001-0408.2023.12.11.

摘要

目的

研究新型有机阳离子转运体2（OCTN2）与前列腺癌细胞对奥沙利铂化疗敏感性的相关性。

方法

收集行前列腺癌根治术患者的前列腺癌组织标本，采用免疫组化法检查组织中的OCTN2蛋白表达；培养标本原代细胞得到前列腺癌细胞株。采用电感耦合等离子体质谱法检测癌细胞对低浓度（0.1 μmol/L）奥沙利铂的摄取量，采用Real time PCR及Western blot法检测癌细胞中OCTN2 mRNA及蛋白的表达水平；选择OCTN2蛋白表达最高及最低的前列腺癌细胞株，采用三磷酸腺苷肿瘤药物敏感性检测法（ATP-TCA）计算奥沙利铂对癌细胞的半数抑制浓度（IC

）；采用MTT法检测血药峰浓度奥沙利铂（50 μmol/L）对前列腺癌细胞的抑制率。采用Spearman法分析前列腺癌细胞对奥沙利铂摄取量与奥沙利铂对前列腺癌细胞抑制率及OCTN2 mRNA表达的相关性。

结果

OCTN2定位于癌细胞膜；癌细胞对奥沙利铂的摄取量为0.283±0.264（

＝12）；不同癌细胞中OCTN2 mRNA和蛋白表达差异明显；OCTN2高表达的癌细胞对奥沙利铂的敏感性（IC

为4.61 μmol/L）高于OCTN2低表达的癌细胞（IC

为26.23 μmol/L）。奥沙利铂对癌细胞的抑制率为（25.4±10.8）%（

＝12）。前列腺癌细胞对奥沙利铂的摄取量与奥沙利铂对前列腺癌细胞的增殖抑制率及前列腺癌细胞中OCTN2 mRNA表达水平三者间存在相关性（

＜0.05）。

结论

OCTN2高表达可能促进前列腺癌细胞对奥沙利铂的摄取，其表达水平可作为预测前列腺癌细胞对奥沙利铂化疗敏感性的参考依据之一。

Abstract

OBJECTIVE

To study the correlation of novel organic cation transporter 2 （OCTN2） with the chemosensitivity of prostate cancer cells to oxaliplatin.

METHODS

Tumor samples of patients receiving radical prostatectomy were collected， and OCTN2 protein was detected with immunohistochemistry； the primary cells of the specimen were cultivated to obtain prostate cancer cell line. Inductively coupled plasma mass spectrometry was used to detect the uptake of low concentration （0.1 μmol/L） of oxaliplatin by cancer cells. Real-time PCR and Western blot were used to detect the mRNA and protein expressions of OCTN2 in cancer cells； the prostate cancer cells with the highest and lowest expression of OCTN2 protein were selected， and IC

of oxaliplatin to prostate cancer cells was analyzed by ATP-TCA method. The inhibitory rate of plasma peak concentration of oxaliplatin （50 μmol/L） to prostate cancer cells was detected by MTT assay. Spearman method was used to analyze the relationship of the uptake of oxaliplatin by prostate cancer cells with inhibitory rate of oxaliplatin to prostate cancer cells and mRNA expressions of OCTN2.

RESULTS

OCTN2 was located on the membrane of cancer cells， and the uptake of oxaliplatin by cancer cells was 0.283±0.264 （

＝12）. The mRNA and protein expression of OCTN2 varied significantly among different cancer cells. The sensitivity of cancer cells with high expression of OCTN2 to oxaliplatin （IC

of 4.61 μmol/L） was higher than that of cancer cells with lower expression of OCTN2 （IC

of 26.23 μmol/L）. The inhibitory rate of oxaliplatin to cancer cells was （25.4±10.8）% （

＝12）. There was a correlation between the uptake of oxaliplatin by prostate cancer cells and the inhibition rate of oxaliplatin to prostate cancer cells and mRNA expression of OCTN2 （

＜0.05）.

CONCLUSIONS

High-expressed OCTN2 may promote the uptake of oxaliplatin by prostate cancer cells， and its expression can serve as a reference for predicting the sensitivity of prostate cancer cells to oxaliplatin chemotherapy.

关键词

新型有机阳离子转运体2奥沙利铂前列腺癌细胞化疗敏感性

Keywords

oxaliplatinprostate cancer cellchemosensitivity

references

FERLAY J，SHIN H R，BRAY F，et al. Estimates of worldwide burden of cancer in 2008：GLOBOCAN 2008[J]. Int J Cancer，2010，127（12）：2893-2917.

潘剑，朱耀，戴波，等. 2022年度前列腺癌基础研究及临床诊疗新进展[J]. 中国癌症杂志，2023，33（3）：210-217.

SUER E，HAMIDI N，AKPINAR C，et al. The effect of time to castration resistance on overall survival and success of docetaxel treatment in castration resistant prostate cancer patients[J]. Urol J，2019，16（5）：453-457.

ARMSTRONG A J，GEORGE D J. Satraplatin in the treatment of hormone-refractory metastatic prostate cancer[J]. Ther Clin Risk Manag，2007，3（5）：877-883.

APARICIO A M，HARZSTARK A L，CORN P G，et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer[J]. Clin Cancer Res，2013，19（13）：3621-3630.

冯建勇，陶晶，沈志远，等. 培美曲塞联合奥沙利铂二线化疗治疗转移性去势抵抗性前列腺癌初步观察[J]. 中国男科学杂志，2016，30（7）：8-10，15.

AHMAD S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes[J]. Chem Biodivers，2010，7（3）：543-566.

POCHINI L，SCALISE M，GALLUCCIO M，et al. OCTN cation transporters in health and disease：role as drug targets and assay development[J]. J Biomol Screen，2013，18（8）：851-867.

SCALISE M，GALLUCCIO M，ACCARDI R，et al. Human OCTN2（SLC22A5）is down-regulated in virus- and nonvirus-mediated cancer[J]. Cell Biochem Funct，2012，30（5）：419-425.

INGOGLIA F，VISIGALLI R，ROTOLI B M，et al. Functional activity of L-carnitine transporters in human airway epithelial cells[J]. Biochim Biophys Acta，2016，1858（2）：210-219.

SUGIURA T，KATO S，SHIMIZU T，et al. Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver[J]. Drug Metab Dispos，2010，38（10）：1665-1672.

QU Q，QU J，GUO Y，et al. Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARγ/OCTN2 pathway[J]. Anticancer Drugs，2014，25（9）：1016-1027.

ANDREWS PA，VELURY S，MANN SC，et al. Cis-diamminedichloroplatinum（Ⅱ）accumulation in sensitive and resistant human ovarian carcinoma cells[J]. Cancer Res，1988，48（1）：68-73.

KELLAND L. The resurgence of platinum-based cancer chemotherapy[J]. Nat Rev Cancer，2007，7（8）：573-584.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

XPC基因单核苷酸多态性与肺癌相关性的研究进展